Daniel Lorenzatti: EAT is not Just a Bystander but Also a Great Modifiable Therapeutic Target
Daniel Lorenzatti, Associate Research Scientist at Montefiore Health System and Cardiologist at Hospital Universitari de Vic, shared a post on LinkedIn about a recent article he and his colleagues co-authored:
“Excited to share our latest research published in JACC: Cardiovascular Imaging!
‘Epicardial Adipose Tissue, Coronary Plaque Progression, and Major Adverse Cardiovascular Events: A Multicenter Study’
From the PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) registry – 773 patients using serial coronary CTA over a median 8-year follow-up.
- Higher EAT volume (EATv) is independently associated with CAD.
- EATv predicts both plaque progression (PP) and rapid plaque progression (RPP) – independent of traditional CV risk factors
- Noncalcified plaque showed nearly 7 times greater progression in the highest vs. lowest EATv tertile
- Patients with PP and RPP had significantly worse 10 – year MACE-free survival (log-rank P equales 0.003 and Pis is lower than 0.001)
EAT quantification – already obtainable from a standard coronary CTA acquisition – can refine risk stratification and identify patients who may benefit from earlier or more intensive preventive therapy.
EAT is not just a bystander; it may be a modifiable therapeutic target.
Proud to work alongside Annalisa Filtz under the guidance of Leandro Slipczuk in this multicenter effort.
Thanks to all the co – authors and specially to the Montefiore Health System incredible team!”
Title: Epicardial Adipose Tissue, Coronary Plaque Progression, and Major Adverse Cardiovascular Events: A Multicenter Study
Authors: Annalisa Filtz, Daniel Lorenzatti, Andrea Scotti, Kirtipal Bhatia, Felipe Contreras Yametti, Franco J. Cossettini, Hyuk-Jae Chang, Sang-Eun Lee, Piotr J. Slomka, Daniel S. Berman, Deepak L. Bhatt, Fay Y. Lin, Damini Dey, Leslee J. Shaw, Leandro Slipczuk
Read Full Article on JACC
Stay updated on Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers